Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483872 | 1.00 | KMT2A (0.49) | KMT2APTGS2ESR2GCKEPHX1 | |
| SCHEMBL1581754 | 1.00 | KMT2A (0.49) | KMT2APTGS2ESR2GCKEPHX1 | |
| SCHEMBL4486333 | 0.99 | KMT2A (0.47) | KMT2APTGS2GCKEPHX1 | |
| SCHEMBL1582005 | 0.99 | KMT2A (0.47) | KMT2APTGS2GCKEPHX1 | |
| SCHEMBL1582009 | 0.99 | KMT2A (0.47) | KMT2APTGS2GCKEPHX1 | |
| SCHEMBL1582258 | 0.85 | KMT2A (0.35) | KMT2AMEN1 | |
| SCHEMBL1582262 | 0.85 | KMT2A (0.35) | KMT2AMEN1 | |
| SCHEMBL1581741 | 0.85 | KMT2A (0.43) | KMT2APTGS2MEN1 | |
| SCHEMBL1581744 | 0.85 | KMT2A (0.43) | KMT2APTGS2MEN1 | |
| SCHEMBL4472935 | 0.84 | ALDH1A1 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585739-B1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | LILLY CO ELI (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | KMT2A 1603/4885PTGS2 1483/4885ESR2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.